AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 122 min read$ABBV

AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings At ACG 2026

AbbVie presented 22 abstracts at ACG 2026, highlighting long-term data for SKYRIZI and RINVOQ in treating IBD. Phase 3 AFFIRM trial showed SKYRIZI's efficacy in Crohn's disease, with 74.5% of patients with fistulizing Crohn's disease achieving no draining fistulas after five years. RINVOQ also showed sustained improvements in difficult-to-treat Crohn's disease. ABBV stock closed at $276.47, up 1.49%.

Original reporting
rttnews.com
Published Oct 12, 2026, 5:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 5:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings At ACG 2026 — source image
Source · rttnews.com
Decision brief

The 30-second read

$ABBVBullishMed
01

Why it matters

The data suggest durable efficacy across multiple IBD subpopulations, supporting broader label expansions and potentially boosting AbbVie's revenue outlook.

02

Market read

First public disclosure of significant Phase 3 and long-term data for two key IBD therapies, likely to influence AbbVie's stock and sector sentiment.

03

What to watch

Potential safety concerns, pricing pressures, and competition from biosimilars could limit the commercial upside of SKYRIZI and RINVOQ.

Relevance 7/10Novelty 7/10Timing: today

Background

AbbVie highlighted 22 abstracts at the American College of Gastroenterology meeting, focusing on new Phase 3 and long-term extension data for its IBD drugs SKYRIZI (risankizumab) and RINVOQ (upadacitinib).

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie presented new Phase 3 AFFIRM data and long-term extension results for SKYRIZI and RINVOQ at the ACG 2026 meeting.

Expected impact

likely upward pressure as the market prices in stronger efficacy data for SKYRIZI and RINVOQ

Evidence & confidence

First disclosure of robust Phase 3 and long-term extension results for two key drugs; data support expanded indications and could drive sales growth.

Market effects

Sector

Strengthens the biotech sector's outlook on IBD therapeutics and may lift peers developing IL-23 or JAK inhibitors.

Regional

U.S. biotech stocks could see modest gains; European IBD drug makers may face heightened competition.

Global

Adds confidence to global investors tracking advanced therapy pipelines for Crohn's disease and ulcerative colitis.

Counterpoint

What could challenge this read

If the data fail to translate into regulatory approvals or market uptake, the hype could fade and the stock may underperform.

Key entities

  • company
    AbbVie Inc.

    Pharmaceutical company presenting IBD data.

  • drug
    SKYRIZI

    IL-23 inhibitor in Phase 3 AFFIRM trial.

  • drug
    RINVOQ

    JAK inhibitor with real-world evidence.

Read at source← All news

StoryAbbVie presents 22 IBD abstracts at ACG 2026, highlighting SKYRIZI and RINVOQ data

Also covered by

1 outlet

Related articles

OCT 11
$ABBVMedAI 8/10

AbbVie (ABBV) Highlights Promising IBD Data at ACG 2026 Amid Div

AbbVie (ABBV) presented 22 IBD research abstracts at ACG 2026, including Phase 3 data for SKYRIZI showing improved Crohn’s disease outcomes. The company offers a 2.46% dividend yield with a 85% payout ratio and 5.2% 3-year growth. GuruFocus values ABBV at $221.92, suggesting 24.6% overvaluation. Insiders sold $17.7M shares, while 18 gurus hold positions with mixed activity.

gurufocus.com3 min
OCT 10
$ABBVMed

AbbVie's Experimental Cancer Drug Temab-A Earns Two FDA Breakthrough Designations for Advanced Colorectal and Lung Cancers

AbbVie's experimental cancer drug, Temab-A, received two FDA Breakthrough Therapy designations for advanced colorectal and lung cancers. The designations expedite development and review but are not approvals. Temab-A targets the c-Met protein and is being tested in combination with bevacizumab for colorectal cancer and as a monotherapy for lung cancer. Early phase 1 data showed promising but preliminary results. The drug is not yet approved and is still under investigation in phase 3 trials.

medicaldaily.com3 min
OCT 10
$ABBVMed

American Hospital Association Sues Over 340B Pilot Program Invol

The American Hospital Association sued to block a 340B Drug Pricing Program pilot starting January 1, 2027, involving AbbVie (ABBV) and Pfizer. The AHA argues the program doesn't compensate hospitals for added costs. AbbVie's stock is 24.6% overvalued, with a 2.46% dividend yield and 85% payout ratio. Its GF Score is 76, showing strong profitability but concerns over valuation and momentum.

gurufocus.com3 min
OCT 9
$ABBVMed

A Milestone in Colorectal and Lung Cancer

AbbVie announced that the FDA granted Breakthrough Therapy Designations for its investigational treatments in colorectal and lung cancer. According to the company, this milestone highlights its commitment to innovation in oncology. Michael Burns, a Pfizer executive, congratulated AbbVie on the progress of the treatment, which was previously developed with Pfizer's involvement.

oncodaily.com1 min